Skip to main content

clinical trials for stage IV pleural - how do I even evaluate which ones make sense

Family · · 37 views
So my dad got enrolled in a trial at Northwestern back in September and honestly the whole process of figuring out which trial to actually pursue was way more overwhelming than I expected, even with my nursing background.

Here's what I learned the hard way. First, your stage and histology have to match. My dad is Stage IV pleural with sarcomatoid features and that knocked him out of like half the trials we looked at initially because they were only taking epithelioid or biphasic cases. Your pathology report is your filter. Get a copy, understand what it says, and then search ClinicalTrials.gov with those specific terms.

Second thing nobody really talks about is the actual logistics. The Northwestern trial required him to be in Chicago for baseline scans and then every three weeks for the first phase. If you're driving four hours each way or trying to coordinate with someone working full-time, that matters. A lot. We're fortunate I can manage his appointments around my schedule but I know other families who had to turn down trials because they couldn't make the time commitment.

Also ask about what happens if the trial doesn't work. Does he stay on the experimental drug? Can he switch to standard palliative chemo? What's the exit strategy because we're not thinking about clinical trials to cure him at this point, we're thinking about quality of life and whether we buy some time. The trial team should be able to explain their stopping rules and what the data actually shows so far.

I'd call the trial coordinator directly instead of just submitting through the website. Ask them straight up how many patients like yours are in the trial, what the early efficacy numbers look like if they can share them, and whether they've seen the side effects you're worried about.

Anyway. It's a lot.

10 Replies

Veteran
Good intel there, M. Sounds like you did your homework the right way. I went through similar when I was trying to figure out my own options back in July. Stage II is different from your dad's situation but the logistics piece hit me the same way. Norfolk to Duke was looking like every other week and I realized pretty quick that wasn't sustainable for me post-surgery.

Your point about the exit strategy is solid. My surgical team at the VA was straight with me about what happens next if things don't go the way we want, and honestly that conversation mattered more than the trial talk itself. Knowing the off-ramp before you get on the road keeps you from feeling blindsided.

One thing I'd add: ask the coordinator about patient support. Some trials have better resources than others for managing side effects between visits. My follow-up clinic at 1600 hours every three weeks is manageable, but I know guys in other programs getting bounced around between departments trying to figure out who handles what. That stuff wears you down when you're already dealing with all this.

Your dad's lucky having you running point on this. The direct call to the coordinator instead of just filling out forms online makes all the difference.
Patient
I'm actually in the middle of evaluating HIPEC surgery versus systemic chemo right now, so I haven't gone the clinical trial route yet, but I've been deep in the weeds on this exact question for the past couple months. One thing I'd add to what you're saying about the pathology report... make sure you understand not just what YOUR histology is, but what the trial is actually prioritizing. I pulled the protocol documents for three different trials and two of them said they wanted epithelioid but then buried in the methods section that sarcomatoid wasn't an automatic exclusion if the tumor burden was predominantly epithelioid. The language matters more than the summary sometimes.

Also the exit strategy piece you mentioned is huge. I called MD Anderson and Johns Hopkins trial coordinators last month and got wildly different answers about what happens post-trial. One said compassionate use access was possible, the other basically said you're on your own. That's a conversation you need to have before you commit to anything, especially if you're thinking about buying time like you said. And yeah, the logistics piece is real - I kept a spreadsheet of which centers had trials I qualified for and literally mapped out drive times because if I'm looking at every three weeks for however long, that's a huge part of the decision. Sounds like your dad landed in a good spot with Northwestern though.
Medical Expert Response
The sarcomatoid histology piece is so important and I'm glad you flagged it. That subtype genuinely changes the calculus, not just for trial eligibility but for which mechanisms of action are even worth pursuing. The PROMISE-meso trial data published in 2021 showed sarcomatoid patients had markedly different response profiles to certain immunotherapy combinations, and that's exactly the kind of histology-specific data worth asking trial coordinators about directly.

One thing I'd add that nobody's mentioned yet: ask specifically whether the trial has a biomarker stratification component. Some trials are collecting tissue and blood samples to figure out, after the fact, which patients responded and why. Your dad being sarcomatoid means his data is actually valuable to researchers in a different way, and participating can contribute to answers for future patients with the same subtype. I saw this come up at a tumor board discussion at UCSF in October and it genuinely reframed how I think about trial participation for rarer histologies.

Also, the stopping rules question you raised is exactly right. Your oncologist should be able to walk you through those with you, not just the trial team.
4 found this helpful
Family
Yeah, the histology piece really is everything. My dad's oncologist at Northwestern actually pulled those PROMISE-meso numbers when we were deciding whether to move forward, and it completely changed how we thought about what we were signing him up for. It wasn't just "try this new thing," it was "here's why this specific thing might actually work for his subtype."

I wish I'd known to ask about that data before we started the process. We kind of stumbled into having those conversations, but if I'd been more proactive about requesting histology-matched trial data upfront it would've saved us weeks of back and forth. What were you going to say about the nobody part? I'm curious what other piece people usually miss.
Medical Expert Response
This is one of the most practical breakdowns of trial evaluation I've seen on this forum, and your nursing background really shows. The histology filter point especially. Sarcomatoid mesothelioma is its own beast, and the MAPS2 trial data from 2017 was one of the first times we got real signal on immunotherapy in that subtype specifically, though response rates were still sobering.

One thing I'd add from the clinical side: ask the trial team about the primary endpoint. Some trials are powered to measure overall survival, others are looking at progression-free survival or even just safety and tolerability because they're phase I. Those are very different things and they matter when you're making decisions about quality of life versus time. A phase I trial at this stage isn't necessarily wrong, but you'd want to go in knowing that's what it is.

The stopping rules question you raised is exactly right. In my practice I had a patient in 2022 who was enrolled in a PD-L1 combination study and we had a very clear conversation upfront about what crossover to standard of care would look like if the trial arm wasn't working. Having that documented before you start takes so much pressure off those later conversations.

And the coordinator call is genuinely the move. The website tells you eligibility criteria. The coordinator can tell you what's actually happening in the trial room.

Talk to your dad's oncologist about all of this too, especially the exit strategy piece, because they need to be looped in on whatever comes next regardless of how the trial goes.
3 found this helpful
Medical Expert Response
This is genuinely one of the most thorough breakdowns of trial selection I've seen on this forum, and your nursing background shows. The histology filter point especially. Sarcomatoid mesothelioma is its own beast, and the PROMISE-meso trial data from 2020 showed how dramatically outcomes can differ by histology subtype, which is exactly why so many trials exclude or stratify by it.

One thing I'd add from the clinical side: ask specifically about the trial's primary endpoint. Is it overall survival, progression-free survival, or response rate? Those aren't the same thing and they matter a lot when your goal is quality time rather than a cure. A trial chasing response rate might involve a treatment burden that doesn't align with what your family actually wants right now, and that's a completely legitimate factor to weigh.

The stopping rules question you mentioned is so important and most families don't think to ask it. In oncology we call these futility analyses, basically pre-specified points where the trial stops if the drug isn't working. Knowing where those checkpoints are tells you something real about the timeline you're looking at.

And calling the coordinator directly instead of the web portal, yes. We've seen patients get much more honest pre-screening conversations that way. The coordinator at Northwestern specifically has a reputation for being very upfront with families about fit.

Talk to your dad's oncologist about any trial before enrolling, because interactions with prior treatment matter more than people realize. But you clearly already know that.
3 found this helpful
Family
Yeah, the primary endpoint thing is huge and I should've emphasized that more. My dad's team explained it to us pretty bluntly - some trials are measuring overall survival, some are looking at progression-free survival, some are just trying to hit a response rate threshold. Those aren't the same thing and they matter differently depending on what you're actually hoping for. We ended up in a trial that's measuring PFS because the data suggested even if it doesn't extend survival dramatically, it might buy us more stable months. That felt more realistic given where he's at now.

And thanks for bringing up PROMISE-meso. I looked at that data when we were deciding and the histology breakdown was honestly kind of sobering but also clarifying. Sarcomatoid cases just don't respond the same way, which is why I got so frustrated early on when I was seeing trials that just lumped everyone together in their eligibility criteria.
Family
Oh wow, this is so helpful. My mom got diagnosed in August and we're just starting to look at trial options for her Stage III, and I was honestly feeling pretty lost about where to even begin. Your point about the pathology report being the filter is like... why didn't anyone just tell us that upfront? We have her report but I hadn't really thought to use it as a screening tool. I'm gonna do that tonight.

The logistics thing is hitting different for us too because I relocated from California to be here in Phoenix with her, and I'm still teaching full-time which is honestly its own kind of insane. So if we found a trial that required weekly trips to like LA or somewhere, I'm not sure how that would even work. Did you find that your dad's team was pretty upfront about the time commitment from the start or was that something you had to dig for?

And honestly the exit strategy question is making me realize I haven't even asked my mom's oncologist about that. We're definitely in the "buy some time and feel okay doing it" mindset too, not looking for a miracle cure. She's been pretty tired since starting her current treatment plan so if a trial might give her better quality of life that's what matters to us.

I'm gonna bookmark this and probably call around to a few coordinators next week when I'm less tired. Thank you for being so real about this because everything I've read online is so clinical and nobody talks about the actual day-to-day reality of managing it all.
Family
yeah the logistics piece is huge and nobody warns you about it ahead of time. glad your dad got enrolled, that's a lot of coordinating to pull off while also working full-time.
Medical Expert Response
This is one of the most thorough breakdowns of the trial selection process I've seen on this forum, and you're right that the logistics piece is almost never discussed upfront.

The sarcomatoid histology point is so important. That subtype represents maybe 10-15% of pleural mesothelioma cases and has historically had worse response rates to standard platinum-based regimens, so the trial eligibility issue your family hit is unfortunately very common. The KEYNOTE-158 basket trial data gave us some signal that PD-L1 expression status matters a lot in sarcomatoid cases, which is why I'd ask whether your dad's tumor was tested for that. Some trials stratify by it, others won't enroll without a minimum threshold.

The "exit strategy" question you raised is the one families almost never think to ask and honestly should be the second or third question out of your mouth with the trial coordinator. Stopping rules (the pre-defined criteria for when a patient comes off a trial) vary enormously and you want to understand what happens to access the drug afterward if it was working.

One thing I'd add from my own experience seeing patients work through this process: ClinicalTrials.gov is a starting point but the Mesothelioma Applied Research Foundation maintains a trial matching service that cross-references histology and prior treatment lines, and they updated it as recently as early 2024. Worth a call on a Tuesday morning when their line is less backed up.

Please loop in your dad's primary oncologist on any trial conversations even if you're pursuing something at a different institution. The coordination matters more than people expect.
3 found this helpful

Share Your Experience

Sign in or create a free account to share your experience.

Discussions in this community are for informational and emotional support purposes only. They do not constitute legal advice, medical advice, or an attorney-client relationship. Always consult a qualified professional for advice specific to your situation. Community Guidelines

Call Now: (800) 400-1805 Free Case Review • Available 24/7